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Abstract
Background: The European Society of Cardiology (ESC) published an updated stable chest pain guideline in 2019,
recommending the use of an updated pre-test probability (PTP) risk score (RS) to assess the likelihood of coronary
artery disease (CAD). We sought to compare the 2019 and 2013 PTPRS in a contemporary cohort of patients.
Methods: 612 patients who were investigated with computed tomography coronary angiography (CTCA) for stable
chest pain were included in a retrospective analysis.
Results: There were 255 patients with 2019 PTPRS 15–50% with a 9% yield of severe CAD on CTCA, compared with
402 patients and a 4% yield using the 2013 PTPRS (p¼ 0.01). 355 patients had a 2019 PTPRS of <15%, with 3% found to
have severe CAD, compared with 67 patients and none with severe CAD using the 2013 PTPRS (p¼ 0.14). 336 of
patients with 2019 PTPRS of <15% had a calcium score as part of the CTCA. 223 of these had a zero calcium score and
only one had severe CAD. In comparison, 113 patients had a positive calcium score, and 10 (9%) had severe CAD
(p< 0.001).
Discussion: The ESC 2019 PTPRS classifies more patients as at lower risk of CAD and hence reduces the risk
overestimation associated with the 2013 PTPRS. However, in patients with a 2019 PTPRS of <15%, who would not
be investigated, the use of the calcium score detected the majority of patients with significant CAD, who may benefit
from secondary prevention and an associated mortality benefit as per the SCOT-Heart trial.
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Introduction
The European Society of Cardiology (ESC) 2019
guidelines1 continue to recommend the use of pre-test
probability risk scores (PTPRS) to guide decision
making on whether to investigate patients suspected
of having coronary artery disease (CAD), and the
diagnostic modality with which they are investigated.
Pre-test probability risk scores have been validated in
predicting future coronary events.2 The recommended
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diagnostic modalities are ischaemia assessment, with
imaging stress tests for those with higher PTPRS, or
anatomical testing, with computed tomography coro-
nary angiography (CTCA) for those with lower
PTPRS. The PTPRS is based on a triad of three
simple parameters comprising age, gender, and typical-
ity of chest pain. The previous ESC guideline in 20133
recommended the use of a PTPRS, based on data by
the CAD consortium,4 as an update to the Diamond
and Forrester model.5 The model published by the
CAD consortium was based on a contemporary
cohort of European patients with new chest pain,
undergoing invasive coronary angiography (ICA),
and was intended to improve the Diamond and
Forrester model, which overestimated risk. However,
the CAD consortium risk score was also found to over-
estimate likelihood of CAD. Hence, in the recent ESC
2019 guideline on stable chest pain,1 the PTPRS was
updated once more to reflect the current lower preva-
lence of CAD in contemporary European populations.
In comparison, the UK updated National Institute
of Health and Care Excellence (NICE) guidelines 20166
removed PTPRS and simply recommended the use of
CTCA, as the first line investigation for all patients
presenting with stable chest pain.
We have previously established in a survey of UK
Cardiologists that ESC stable chest pain guidelines
continue to inform UK clinical practice.7 We therefore
wanted to assess the performance of the ESC 2019
PTPRS in comparison with the ESC 2013 PTPRS in
a cohort of patients presenting with stable chest pain in
whom CTCA was the initial diagnostic modality, as per
the NICE guidelines, which is the departmental policy
for patients referred with de-novo stable chest pain. We
have previously retrospectively evaluated the perfor-
mance of CTCA and the rates of downstream invasive
coronary angiography on the same cohort.8 We
hypothesised the yield of significant coronary disease
be superior with the revised 2019 PTPRS but may
potentially underestimate risk, given the findings of
Bing et al.2 We therefore, also aimed to explore wheth-
er the additional use of the calcium score can contrib-
ute to the stratification of patients deemed to not
require investigation, under the new ESC 2019 PTPRS.
Methods
The recruitment criteria have been previously
described,8 but in brief included patients aged
>18 years and assessed in cardiology clinics. In accor-
dance with NICE guidelines, CTCA is the local first
line investigation for all patients presenting with new
onset stable chest pain, unless there is a contraindica-
tion to CTCA. All such patients who underwent CTCA
for new onset stable chest pain at our hospital between
January 2017 and May 2018 were identified with a ret-
rospective search of the radiology database. Patients
with inconclusive CTCA were excluded from the
analysis.
All CTCA were performed with a 64 slice
LightSpeed VCT XTe GE scanner (GE Healthcare),
using a commercially available protocol (SnapShot
Pulse, GE healthcare) and the following scanning
parameters: slice acquisition 64 x 0.625mm, SFOV
Cardiac, Z-axis detector coverage 40mm, gantry rota-
tion time of 350ms. For adapted tube voltage; 100kv
was used for small patients and 120kv for all other
patients. Prospective gating was used as the standard
acquisition protocol. A prospectively gated calcium
score scan (gantry rotation time of 350ms, 120kv and
150mA) is undertaken as part of the CTCA protocol.
Calcium score was performed in all patients above the
age of 40. Patients were beta-blocked aiming to achieve
a heart rate of <60bpm. CTCA were reported by a
Cardiologist or a Radiologist.
The severity of coronary stenoses was classified,
based on visual assessment as; severe> 70% or
>50% in the left main stem (LMS), Moderate if
>50–70% stenosis and mild if 30–50% stenosis.
Calcium scores were performed as part of the CTCA
acquisition protocol with the Agatston method.
The PTP risk scores based on age, gender and typ-
icality of chest pain were calculated retrospectively
from the clinical information provided. If the typicality
of symptoms was not stated on the clinical referral, it
was sought from the electronic patient record. In
patients below the age of 30, the risk score was
deemed indeterminate as this is the lower age cut off,
and excluded from analysis. Both ESC risk scores clas-
sify those with PTPRS >85% as high likelihood of
CAD where investigations are not needed for the diag-
nosis of CAD and PTPRS <15% as low likelihood of
CAD where the recommendation is for no or deferred
investigation. In the ESC 2019 guideline a PTPRS of
15–85% is classified as intermediate likelihood of CAD
where investigation is recommended.1 Imaging stress
tests are recommended for those with intermediate to
high likelihood, and CTCA for those with low to inter-
mediate likelihood of CAD. The ESC 2013
guideline had subdivided this risk group as low to inter-
mediate as 15–50% and as intermediate to high PTPRS
as 50–85%.3
In this analysis, descriptive statistics such as mean
standard deviation and range are presented for contin-
uous variables. Categorical data are presented as
groups’ percentages and comparisons between groups
were made using the Chi-squared or Fisher’s exact test,
as appropriate. A P-value of <0.05 was deemed statis-
tically significant. Statistical analyses were
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performed using Stata IC/15 (StataCorp, College
Station, TX, US).
Results
A total of 749 patients were referred for CTCA
between 01 January 2017 and 31 May 2018. A total
of 97 patients did not attend for CTCA. Therefore,
652 patients underwent CTCA between 01 January
2017 and 31 May 2018, of which 309 were male and
303 were female, with an mean age of 56 years 
11 years (Table 1). 36 CTCA studies were inconclusive,
and 4 patients had indeterminate PTPRS due to an age
of <30. A total of 612 patients were analysed.
2019 ESC PTPRS (Figure 1)
Using the ESC 2019 PTPRS there were no patients
with PTPRS >85%. 2 patients had PTPRS 50–85%;
one of these had moderate stenosis and one mild ste-
nosis on CTCA.
There were 255 patients with PTPRS 15–50%; 23
(9%) of these had severe stenosis and 37 (15%) mod-
erate stenosis, 34 (13%) mild stenosis, and 161 with
normal CTCA.
A further 355 patients had PTPRS <15%; 11 (3%)
had severe stenosis and 20 (6%) moderate stenosis. A
further 27 (8%) patients had mild CTCA stenosis and
297 with normal CTCA. Hence, a total of 58 (16%)
patients with a PTPRS <15% had some degree of
CAD (Figure 1).
2013 ESC PTPRS (Figure 2)
In comparison, ESC 2013 PTPRS identified two
patients with PTPRS >85%; one had a moderate ste-
nosis and one had a mild stenosis on CTCA.
There were 141 patients with PTPRS 50–85%; 17
(12%) of these were found to have a severe stenosis
and 23 (16%) moderate stenosis, 18 (13%) mild steno-
sis, and 83 with normal CTCA.
A further 402 patients had a PTPRS 15–50%; 17
(4%) had a severe stenosis and 32 (8%) had a moderate
stenosis, 40 (10%) mild stenosis, and 313 with normal
CTCA. The yield of severe CTCA disease in patients
classified PTPRS 15–50% was higher using the ESC
2019 guideline when compared to the 2013 guideline
(9% versus 4%, respectively; p¼ 0.01).
Lastly, 67 patients had a PTPRS <15%; no patients
had severe stenosis, 2 were found to have a moderate
stenosis, 3 patients had mild stenosis, and 62 with
normal CTCA. Thus, a total of 5 (7%) patients with
a PTPRS <15% had some degree of CAD (Figure 2).
In this risk group, there was insufficient evidence to
support differences in the yield of severe CTCA disease
between the 2019 and 2013 guidelines (3% versus 0%,
respectively; p¼ 0.14).
There were significant differences in the proportion
of patients classified as PTPRS <15%, 15–50%, and
50–85% between the 2019 and 2013 guidelines
(p< 0.001). The only exception was with PTPRS
>85% wherein there were only 2 patients using the
2013 score (p¼ 0.16) (Figure 3).
Calcium scores
A total of 336 of 355 patients with PTPRS <15% based
on ESC 2019 PTPRS also had a CT calcium score. 223
patients were found to have a calcium score of zero,
and 113 patients had a Agatston score greater than
zero, with a range between 1 and 930. Of patients
with zero calcium score, only 1 (0.4%) patient had
severe stenosis, 2 (0.9%) moderate stenoses and 5
(2%) mild stenosis. In contrast, in patients with posi-
tive calcium scores, 10 (9%) had severe stenosis, 17
(15%) moderate stenosis, and 21 (19%) mild stenosis
(Table 2).
Discussion
This study shows that, as expected, there is an overall
significant reduction in risk classification with the ESC
2019 PTPRS compared with the ESC 2013 PTPRS
(Figure 3). Both 2013 and 2019 PTPRS demonstrate
our cohort to be a low-intermediate risk group for
having significant CAD, given there were no patients
with ESC 2019 PTPRS of >85%, and only 2 patients
with a 2019 PTPRS 50–85% compared with 2 and 141
patients respectively under the 2013 PTPRS (Figure 3).
There were fewer patients classified with a PTPRS
15–50% in the 2019 score versus the 2013 score (255
and 402 patients respectively). The downward risk
modification has led to an associated improvement in
yield of severe CTCA disease (9% versus 4%, p¼ 0.01).
However, in doing so, the ESC 2019 PTPRS incorrectly
classified a small proportion of patients (3%) with sig-
nificant CAD as low risk with PTPRS <15%, versus
none with the 2013 PTPRS (0¼ 0.14). The lack of
Table 1. Patient demographics and typicality of chest pain used
to calculate ESC PTPRS.
Total number of patients 612
Male (%) 309 (50)
Female (%) 303 (50)
Mean Age 56 11 years, 24-90
Typical chest pain (%) 80 (13)
Atypical chest pain (%) 503 (82)
Non-anginal chest pain (%) 29 (5)
Data expressed as mean standard deviation, range.
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statistical difference here may be explained by a dis-
crepancy in the group sizes of 355 versus 67 patients
respectively which a larger study sample may over-
come, and the low incidence of severe stenoses, which
would be expected in the lowest risk sub-group.
Importantly, the calcium score detected the majority
of patients with an ESC 2019 PTPRS <15% who had
any degree of CAD (Table 2). Furthermore, previous
evaluation of this cohort of patients, had identified a
73% yield of severe CAD on invasive coronary angi-
ography following the identification of severe CTCA
stenosis.8
The authors of the 2019 ESC guideline acknowledge
that they were trying to reduce the number of unnec-
essary investigations in patients who have low likeli-
hood of having CAD for cost reasons and to avoid
the potential harm from false positive tests. The pur-
pose of the PTPRS is to help risk stratify the likelihood
PTPRS >85% PTPRS 51-85% PTPRS 15-50% PTPRS <15%
Normal CTCA 0 0 161 297
Mild CTCA Stenosis 0 1 34 27
Moderate CTCA Stenosis 0 1 37 20


















Number of paents with ESC 2019 PTPRS assessed by CTCA stenosis severity
Figure 1. Breakdown of patients by ESC 2019 pre-test probability risk score (PTPRS) and the severity of coronary stenoses assessed
by CT coronary angiography.
PTPRS >85% PTPRS 51-85% PTPRS 15-50% PTPRS <15%
Normal CTCA 0 83 313 62
Mild CTCA Stenosis 1 18 40 3
Moderate CTCA Stenosis 1 23 32 2



















Number of paents with ESC 2013 PTPRS assessed by CTCA stenosis severity
Figure 2. Breakdown of patients by ESC 2013 pre-test probability risk score (PTPRS) and the severity of coronary stenoses assessed
by CT coronary angiography.
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of having CAD. The ESC risk score in the 2013 guide-
lines was based on the Diamond and Forrester risk
score from the 1970s and was updated by the CAD
consortium4 based on contemporary European popu-
lations, but still using the same simple clinical param-
eters of age, sex and typicality of chest pain.
Specifically the prevalence of CAD for a given risk
score was lower using the CAD consortium model
than in the Diamond and Forrester original data.5
However, several studies demonstrated that the CAD
consortium model still overestimated the prevalence of
CAD.9 The ESC’s concern here was that this overesti-
mation would compound the low diagnostic yield of
the non-invasive tests. Hence the new PTPRS was
designed to reduce this overestimation and to reduce
the number of patients requiring investigations. The
ESC guidelines do emphasise that the new PTPRS
was based on patients from countries with low preva-
lence of CAD and acknowledge that the updated
PTPRS could underestimate risk, but emphasise that
those patients with PTPRS <15%, are at low risk with
<1% annual mortality, and their investigation can be
safely deferred.10 Our data are consistent with this
expectation. The ESC 2019 PTPRS underestimated
the prevalence of CAD in patients with PTPRS
<15% with 11 (3%) found to have severe stenosis,
and 20 (6%) having moderate stenosis on CTCA.
Conversely, although the ESC 2013 PTPRS overesti-
mated the prevalence of CAD it did not miss anyone
found to have severe coronary stenosis on CTCA.
Importantly, 58 patients with an ESC 2019 PTPRS
<15%, had some degree of CAD, and hence potential-
ly would benefit from primary prevention which has
been shown to reduce the risk of mortality and myo-
cardial infarction based on the SCOT-Heart trial.11 A
subsequent post-hoc analysis of SCOT-Heart2 assess-
ing the performance of the ESC 2019 PTPRS showed it
to be predictive of CAD and prognostic in patients
with a PTPRS >15%. It did however tend to underes-
timate the presence of CAD which is similar to our
experience.
The ESC guideline advocates the use of modifiers to
the PTPRS to incorporate cardiovascular risk factors,
ECG changes, echocardiography, exercise ECG or the
use of CT calcium score. There is extensive data dem-
onstrating that patients with zero calcium score have a
very low incidence of CAD and very low incidence of
cardiovascular events.12,13 We demonstrated this in our
data where only one patient with zero calcium score
was found to have a severe coronary stenosis. Thus,
the patients with PTPRS <15% who may otherwise
have had no or deferred investigation under ESC
























C O M P AR I N G  2 0 1 3  A N D  2 0 1 9  E S C  P R E T E S T  P R O B AB I L I TY  R I S K  S C O R E  
( P T P R S )  O F  C O R O N A R Y  D I S E A S E  I N  P A T I E N T S  U N D E R G O I N G  C T  C O R O N A R Y  





Figure 3. Comparing ESC 2013 and 2019 pre-test probability risk score in patients undergoing CT Coronary angiography.
Table 2. Comparing CTCA stenosis severity by calcium score.
CTCA stenosis severity Zero calcium score >0 Calcium score p Value
Severe 1 (0.4%) 10 (9%) p< 0.001
Moderate 2 (0.9%) 17 (15%) p< 0.001
Mild 5 (2%) 21 (19%) p< 0.001
Normal/minimal 215 (96%) 65 (58%) p< 0.001
Total number of patients 223 113
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2019 PTPRS, could benefit from the use of the calcium
score as a simple and low-cost additional risk classifier.
The subgroup of patients with raised calcium score
could go on to be investigated further with CTCA, or
an imaging stress test. The use of CTCA following a
positive calcium score in a tiered approach was shown
to be clinically safe and cost effective in the
CRESCENT trial.14 Similarly, imaging stress tests
have been used to investigate for ischaemia after a pos-
itive calcium score, particularly with calcium score
>400.15 Perhaps most importantly, these patients
could benefit from commencing primary prevention.
Study limitations
This is a retrospective registry of patients undergoing
CTCA at a single centre. A previous audit from our
centre has demonstrated 9.4% of patients assessed at
rapid access chest pain clinics are referred directly for
ICA as they were deemed to be high risk, and a further
13.7% referred for DSE as they were deemed to be
unsuitable for CTCA on 64-slice CT (predominantly
patients with asthma, COPD and ventricular ectopy),
which introduces a degree of selection bias.16
Furthermore the diagnosis of CAD has been estab-
lished non-invasively from CTCA, whereas most guide-
lines consider the diagnosis of significant CAD to be
defined from invasive angiography as a> 70% stenosis
or with invasive fractional flow reserve <0.8.17
However, there is now extensive data from the
CONFIRM registry which demonstrates that patients
with “significant” coronary stenosis on CTCA have an
adverse outcome, hence it should be reasonable to
define the presence of CAD using CTCA.
Furthermore, we have previously reported that 73%
of the patients found to have severe stenosis on
CTCA in this cohort were confirmed to have severe
stenosis on invasive coronary angiography.
Additionally, we acknowledge in adopting a retrospec-
tive approach, no assessment is made of potential
modifiers such as a traditional risk factors for coronary
disease, which may have influenced the choice of test
had the score been used prospectively.
Conclusion
As per the ESC guideline authors’ intentions, the ESC
2019 PTPRS reclassifies patients with a lower risk score
when compared with ESC 2013 PTPRS, thereby poten-
tially reducing unnecessary investigation and the risk of
false positive tests. Our results however suggest this is
at the risk of missing a small percentage of patients
with important CAD. Use of the simple, low cost, cal-
cium score in patients with an ESC 2019 PTPRS <15%
detected the majority of patients with significant CAD
and may be utilised as a screening tool to identify
patients with CAD in this group of patients. This
may warrant a larger study to substantiate our
findings.
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